Your SlideShare is downloading. ×
0
Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018

90

Published on

Market Research Reports, Inc. has announced the addition of “OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018” research report to their offering. See more …

Market Research Reports, Inc. has announced the addition of “OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018” research report to their offering. See more at- http://mrr.cm/ZXd

Published in: Healthcare
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
90
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Category : Pharma & Healthcare All logos and Images mentioned on this slide belong to their respective owners. www.MarketResearchReports.com
  • 2. Introduction to Report  Launch Date: August 20, 2014  Number of Pages: 252  Geography Coverage: Global  Available Format: PDF Price For Single User License: USD 5,995 Price For Site User License: USD 11,990 Price For Global User License: USD 17,985 Delivery Time: Within 24 Hours (During Working Days) www.MarketResearchReports.com
  • 3. About the Report The main drivers of growth in graft versus host disease over the 2013-2018 forecast period include the increasing numbers of allogeneic hematopoietic stem cell transplants and the increasing use of biologic off-label and marketed therapies in the 6MM. Sanofi is a key player in the GVHD market with Thymoglobuline and Lemtrada by infiltrating prophylaxis, aGVHD and cGVHD. Gaining more and more ground in the treatment management of cGVHD is Roche’s Rituxan that Publisher estimates will be one of the bestselling biologics in GVHD in the US by 2018. www.MarketResearchReports.com
  • 4. Research Finding The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research. "OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018" report states that this growth, which will occur over six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), will be strongest in the five European countries (5EU), where multiple product launches will accelerate the market value at a CAGR of 9.26% during the forecast period. Several products are due to enter the GVHD market by 2018, with Osiris Therapeutics and Mesoblast’s first-to-market Prochymal expected to generate sales of $12.2 million in 2018. www.MarketResearchReports.com
  • 5. Key Findings High uptake of off-label biologics (Rituxan, Lemtrada, Remicade and Thymoglobuline) No national guidelines are in place GVHD remains a field of highly unattained unmet need No consensus over clinical trial endpoints Regulatory T cells (Tregs) are the focus of the early stage pipeline Huge opportunity exists in the chronic patient segment of GVHD Institutionally funded studies are the core of GVHD treatment management www.MarketResearchReports.com
  • 6. Report Coverage 1. Introduction 2. Disease Overview 3. Epidemiology 4. Current Treatment Options 5. Unmet Need and Opportunity 6. Research and Development Strategies 7. Pipeline Assessment 8. Pipeline and Off-Label Valuation Analysis 9. Appendix www.MarketResearchReports.com
  • 7. Custom Research:  Are you an industry professional, entrepreneur, venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research. For Any Customization Related query Visit IdeaCenter @ http://www.marketresearchreports.com/idea-center www.MarketResearchReports.com
  • 8. How To Buy This Report? Visit following URL to see Table of Content and purchase this publication: http://mrr.cm/ZXd About Market Research Reports, Inc. Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”. Contact : Amitava Sen Email : info@marketresearchreports.com Phone: +1 302-703-7787 (USA) +91-8762746600 (India) www.MarketResearchReports.com

×